Low Risk Drug Category The US Department of Health and Human Services (HHS) has recommended easing marijuana restrictions, a department spokesperson said Wednesday, August 30, 2023, following a review request from the Biden Administration last year. Nearly 40 US states have legalized marijuana use in some form, but it is still completely illegal in some states and at the federal level. Reclassifying marijuana to a level less dangerous than drugs like heroin would be the first step toward broader legalization, a move supported by a majority of Americans.
Cannabis use grading recommendations were provided to the Drug Enforcement Agency (DEA) on Tuesday as part of President Biden’s briefing to HHS, the spokesperson said.
The DEA will now begin its review,” a DEA spokesperson said.
Marijuana is currently classified as a class I drug under the Controlled Substances Act, which means it has a high potential for abuse and is unacceptable for medical use
along with drugs like heroin and LSD.
HHS recommends reclassifying cannabis to have moderate to low dependence potential and lower abuse potential. Which would place it in the ketamine and testosterone classes. If cannabis classification was relaxe at the federal level. This would allow major stock exchanges to list companies involved in the cannabis trade. And potentially allow foreign companies to start selling their products in the United States.
House Press Secretary Karine Jean-Pierre. Marijuana is legal in Canada which in North America has become home to publicly trade marijuana growers and distributors. Most of whom are expect to expand to the United States, if federal legalization follows there. Shares of several cannabis companies including Canopy Growth, Tilray Brands and Cronos Group rose on the news. Companies such as Verano Holdings and Sunburn Cannabis welcomed HHS’ move. Veranos CEO George Archos.